World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
55427
World Ranking
5470
National Ranking
2946

Noopur Raje publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Noopur Raje sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 744 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Noopur Raje D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Noopur Raje sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Noopur Raje is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with significant contributions in hematology, oncology, molecular biology, genetics, and immunology.

Their scholarly output includes over 550 publications in medicine, with a notable emphasis on hematology (238 publications) and oncology (170 publications). Raje's work encompasses various interdisciplinary fields, integrating molecular biology and genetics into their studies.

Raje's research topics extensively cover:

  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research

The scientist has contributed to a variety of frequent publication venues including:

  • Clinical Lymphoma Myeloma & Leukemia (79 publications)
  • Blood (72 publications)
  • Journal of Clinical Oncology (26 publications)
  • Blood Advances (17 publications)
  • Leukemia (10 publications)

Among Raje's recent notable papers are:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results, 2023, Nature Medicine
  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma, 2022, New England Journal of Medicine
  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021, The Lancet Oncology

Raje's research collaborations include frequent co-authors such as:

  • Andrew J. Yee (86 joint publications)
  • Paul G. Richardson (52 joint publications)
  • Andrew R. Branagan (50 joint publications)
  • Nizar J. Bahlis (49 joint publications)
  • Nikhil C. Munshi (48 joint publications)

This body of work demonstrates Raje's active engagement in clinical and molecular research focused on blood cancers and targeted therapies, contributing to advancements in multiple myeloma treatment paradigms and immunotherapy approaches.

Best Publications

  • Multiple myeloma

    Noopur Raje;Kenneth C. Anderson

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

  • Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

    Loredana Santo;Teru Hideshima;Andrew L. Kung;Jen-Chieh Tseng

  • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

    Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch

  • Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

    Mariateresa Fulciniti;Pierfrancesco Tassone;Teru Hideshima;Sonia Vallet

  • Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

    Paul G. Richardson;David S. Siegel;Ravi Vij;Craig C. Hofmeister

  • Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

    Toshiaki Hayashi;Teru Hideshima;Masaharu Akiyama;Klaus Podar

  • Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

    Teru Hideshima;Hiroshi Ikeda;Dharminder Chauhan;Yutaka Okawa

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

    Noopur Raje;Evangelos Terpos;Wolfgang Willenbacher;Kazuyuki Shimizu

  • Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

    Güllü Topal Görgün;Gregory Whitehill;Gregory Whitehill;Jennifer L. Anderson;Jennifer L. Anderson;Teru Hideshima

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma

    M Fulciniti;S Vallet;S Ettenberg;X Shen

Frequent Co-Authors

Teru Hideshima
Teru Hideshima Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Shaji Kumar
Shaji Kumar Mayo Clinic
Klaus Podar
Klaus Podar Karl Landsteiner University of Health Sciences
Robert L. Schlossman
Robert L. Schlossman Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a medical career in the USA opens the door to several related fields with flexible education options. Many students explore alternatives to traditional medicine, such as nursing, healthcare administration, nutrition, or nurse practitioner roles.

Prospective nurses may benefit from nursing schools that don't require teas or other entrance exams. This provides a streamlined path for those ready to begin their nursing journey without additional testing requirements.

For those interested in the administrative side of healthcare, there are healthcare administration degrees available online. These programs can be completed at an accelerated pace, preparing graduates for leadership positions in hospitals and clinics.

Registered nurses aiming to advance their practice can find rn to fnp bridge programs. These specialized paths enable working nurses to become Family Nurse Practitioners more efficiently.

Additionally, those keen on preventative healthcare and wellness may pursue online nutrition degrees. This prepares graduates for careers in nutritional counseling, dietetics, and public health.

Each of these pathways offers unique benefits and may align with your career goals in the wider healthcare sector.

Best Scientists Citing Noopur Raje

Trending Scientists

Recently Published Articles